{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:10:59Z","timestamp":1780081859712,"version":"3.54.0"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,3,2]],"date-time":"2005-03-02T00:00:00Z","timestamp":1109721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess whether spironolactone has beneficial effects on blood pressure (BP), N\u2010terminal propeptide of type\u2003III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type\u2003II diabetics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ten patients with type\u2003II diabetes and hypertension were enrolled in a randomized, double\u2010blind crossover study comparing 4\u2003months\u2019 treatment with spironolactone and placebo with a 4\u2010week washout phase. BP, PIIINP and carotid\u2010radial PWV were measured at the end of each treatment phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with placebo, spironolactone reduced systolic BP by 15.6 \u00b1 46.1\u2003mmHg (<jats:italic>P<\/jats:italic>\u2003=\u20030.005, 95%\u2003CI 2.7\u201328.5\u2003mmHg), PIIINP by 0.6 \u00b1 0.3\u2003\u00b5g\u2003l<jats:sup>\u22121<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003=\u20030.04, 95%\u2003CI 0.02\u20131.1\u2003\u00b5g\u2003l<jats:sup>\u22121<\/jats:sup>) and PWV by 0.6 \u00b1 0.2\u2003m\u2003s<jats:sup>\u22121<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003=\u20030.008, 95%\u2003CI 0.18\u20131.02\u2003m\u2003s<jats:sup>\u22121<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type\u2003II diabetic patients with hypertension.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02363.x","type":"journal-article","created":{"date-parts":[[2005,4,19]],"date-time":"2005-04-19T16:06:58Z","timestamp":1113926818000},"page":"520-523","source":"Crossref","is-referenced-by-count":32,"title":["Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients"],"prefix":"10.1111","volume":"59","author":[{"given":"J.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Band","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Struthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00954.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000033824.02722.F7"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1099"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2002.034"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","unstructured":"DaviesJI BandM MorrisA StruthersAD.Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes.Diabetologia2004:47:1687\u201394.","DOI":"10.1007\/s00125-004-1510-8"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197012000-00001"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/hy0102.099031"},{"key":"e_1_2_5_13_2","first-page":"483","article-title":"Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers","volume":"36","author":"Kahonen M","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-000-0017-z"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02363.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02363.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:04:15Z","timestamp":1697443455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02363.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,2]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02363.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02363.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,2]]}}}